PROF
Profound Medical Corp.
$4.34
+$0.21(+5.08%)
30
Overall
--
Value
18
Tech
42
Quality
Market Cap
$120.65M
Volume
106.08K
52W Range
$3.76 - $9.17
Target Price
$12.31
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $7.3M | $6.9M | $6.7M | $7.2M | $10.7M | ||
| Total Revenue | $7.3M | $6.9M | $6.7M | $7.2M | $10.7M | ||
| COST OF GOODS SOLD | |||||||
| Cost of Revenue | $3.8M | $3.9M | $3.7M | $2.9M | $3.6M | ||
| GROSS PROFIT | |||||||
| Gross Profit | $3.5M | $3.0M | $3.0M | $4.3M | $7.0M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $22.3M | $33.2M | $29.5M | $33.0M | $40.1M | ||
| Research & Development | $9.9M | $15.3M | $14.7M | $14.4M | $17.0M | ||
| Research Expense | -- | -- | $14.7M | $14.4M | $17.0M | ||
| Selling, General & Administrative | $12.4M | $18.0M | $17.9M | $18.5M | $23.1M | ||
| Selling & Marketing Expenses | $4.9M | $7.7M | $8.5M | $9.5M | -- | ||
| General & Administrative Expenses | $7.6M | $10.3M | $9.5M | $18.5M | $23.1M | ||
| Depreciation & Amortization | -- | -- | $-290.0K | -- | -- | ||
| Depreciation & Amortization | -- | -- | $-290.0K | -- | -- | ||
| Amortization | -- | -- | $-290.0K | -- | -- | ||
| Other Operating Expenses | -- | -- | $-3.1M | $575.0K | -- | ||
| OPERATING INCOME | |||||||
| Operating income | $-18.9M | $-30.3M | $-26.5M | $-28.7M | $-33.1M | ||
| EBITDA | $-19.5M | $-28.6M | $-26.6M | $-26.4M | $-26.9M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $543.0K | $67.0K | $174.0K | $770.0K | -- | ||
| Intinc | $692.0K | $205.0K | $803.0K | $1.6M | -- | ||
| Net Non-Operating Interest Income/Expense | $-149.0K | $310.0K | $629.0K | $-726.0K | -- | ||
| Gain on Sale of Securities | $-2.8M | $7.0K | -- | $775.0K | $1.4M | ||
| Other Income/Expense | $-2.9M | $7.0K | $-15.0K | $-775.0K | $-1.4M | ||
| Other Special Charges | -- | -- | $290.0K | $-146.0K | -- | ||
| SPECIAL ITEMS | |||||||
| Restructring And Mn A Income | $90.0K | -- | -- | -- | -- | ||
| Special Income Charges | $90.0K | -- | $-2.5M | -- | -- | ||
| Impairment of Capital Assets | -- | -- | $2.5M | -- | -- | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-21.0M | $-30.5M | $-28.2M | $-27.3M | $-27.8M | ||
| Pre-Tax Income | $-21.6M | $-30.6M | $-28.4M | $-27.3M | $-27.8M | ||
| INCOME TAX | |||||||
| Tax Provision | $45.0K | $105.0K | $287.0K | $-128.0K | $-2.0K | ||
| NET INCOME | |||||||
| Net Income | $-21.6M | $-30.7M | $-28.7M | $-27.2M | $-27.8M | ||
| Net Income (Continuing Operations) | $-21.6M | $-30.7M | $-28.7M | $-27.2M | $-27.8M | ||
| Net Income (Discontinued Operations) | $-21.6M | $-30.7M | $-28.7M | $-27.2M | $-27.8M | ||
| Net Income (Common Stockholders) | $-21.6M | $-30.7M | $-28.7M | $-27.2M | $-27.8M | ||
| Normalized Income | $-15.8M | $-22.5M | $-18.3M | $-27.4M | $-27.8M | ||
| TOTALS | |||||||
| Total Expenses | $-26.2M | $-37.2M | $33.2M | -- | $43.7M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $17.3M | $20.5M | $20.8M | $21.2M | $24.8M | ||
| Average Shares Outstanding (Diluted) | $17.3M | $20.5M | $20.8M | $21.2M | $24.8M | ||
| Shares Outstanding | $19.6M | $20.8M | $20.3M | $30.1M | $30.1M | ||
| Basic EPS | $-1.25 | $-1.5 | $1.38 | $-1.34 | $-1.12 | ||
| Basic EPS (Continuing Operations) | $-1.25 | $-1.5 | $1.38 | $-1.34 | $-1.12 | ||
| Diluted EPS | $-1.25 | $-1.5 | $1.38 | $-1.34 | $-1.12 | ||
| Diluted EPS (Continuing Operations) | $-1.25 | $-1.5 | $1.38 | $-1.34 | $-1.12 | ||
| OTHER METRICS | |||||||
| Other Costof Revenue | -- | -- | $3.7M | $2.9M | $3.6M | ||
| Other Gand A | $7.6M | $10.3M | $9.5M | $18.5M | $23.1M | ||
| Restruct | $90.0K | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PROF | $4.34 | +5.1% | 106.08K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |